Washington, D.C. (August 25, 2014) – The Biotechnology Industry Organization (BIO) today announced the initial list of presenting companies for the 13th Annual BIO Investor Forum. The event is an international investor forum that assembles early and established private companies as well as emerging public biotechs, along with top public and private equity investors, to explore investment trends and opportunities in life sciences. The event will take place October 7-8, 2014 at the Palace Hotel in San Francisco, California.
“Over the past three years, more than 30 of the private companies that presented at a BIO Investor Forum have gone public, generating a current combined market capitalization of nearly $15 billion,” said Jim Greenwood, CEO and President at BIO. “Investors are eager to learn about and evaluate fresh new investment opportunities, as evidenced by the 30% increase in investor registration to date compared to last year.”
Presenting companies have a clear R&D focus with a pipeline involving biotechnology for therapeutics, diagnostics or platform technologies. More than one-quarter of the public presenting companies at the event have gone public since passage of the Jumpstart Our Business Startups (JOBS) Act in April 2012. To date, overall, 111 biotech companies have gone public since passage of the JOBS Act.
New presenting companies are continuously being added. For updates on the list of presenters, please visit here. If you are interested in becoming a presenter, please submit an application here.
The following companies will present at the 13th Annual BIO Investor Forum:
Critical Outcome Technologies Inc.
Protagonist Therapeutics, Inc.
Vivaldi Biosciences Inc.
Catalyst Pharmaceutical Partners
Critical Outcome Technologies
Newron Pharmaceuticals SpA
*Denotes companies who went public since passage of the JOBS Act
Now a staple at the BIO Investor Forum, the event will again host a series of Discovery Track presentations that feature Seed and A-round companies incorporated after 2009 and have raised less than $25M through October 2014. Companies in this track are also first-time presenters and use biotechnology or related technologies for research and development of drug products or diagnostics. The following companies are scheduled to present in the Discovery Track:
ETX Pharma, Inc.
Also presenting in the Discovery Track will be several patient advocacy groups looking for potential research partners:
Juvenile Diabetes Research Foundation
Rare Cancer Research Foundation
New to BIO Investor Forum this year, the Buzz of BIO contest is recognizing “Early Stage Entrepreneurs” and “Late Stage Leaders.” One winner from each category will receive complimentary registration and a company presentation opportunity. Voting opens today, August 25, and winners will be selected by number of votes, on September 4, 2014. Nominees include:
Early Stage Entrepreneur:
Late Stage Leader:
Enable Injections, LLC
To learn more about the BIO Investor Forum, including registration, program and partnering information, please visit here. Media registration is now open for qualified members of the press.